These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19845677

  • 1. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.
    Br J Pharmacol; 2009 Nov; 158(6):1536-47. PubMed ID: 19845677
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
    Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM.
    J Clin Pharmacol; 2011 Apr; 51(4):561-74. PubMed ID: 20622200
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D, Ellis D, Canafax DM, Combs D, Druzgala P, Milner PG, Midei MG.
    Thromb Haemost; 2017 Apr 03; 117(4):706-717. PubMed ID: 28180234
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.
    Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD.
    Circulation; 2009 Sep 22; 120(12):1029-35, 2 p following 1035. PubMed ID: 19738136
    [Abstract] [Full Text] [Related]

  • 8. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants.
    Schwarz UI, Stein CM.
    Clin Pharmacol Ther; 2006 Jul 22; 80(1):7-12. PubMed ID: 16815312
    [No Abstract] [Full Text] [Related]

  • 9. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA.
    Clin Pharmacol Ther; 2006 Apr 22; 79(4):291-302. PubMed ID: 16580898
    [Abstract] [Full Text] [Related]

  • 10. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M.
    Clin Pharmacokinet; 2005 Apr 22; 44(12):1227-46. PubMed ID: 16372822
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenetics of coumarinic oral anticoagulants.
    Manolopoulos VG, Ragia G, Tavridou A.
    Pharmacogenomics; 2010 Apr 22; 11(4):493-6. PubMed ID: 20350128
    [Abstract] [Full Text] [Related]

  • 12. Puerarin offsets the anticoagulation effect of warfarin in rats by inducing rCyps, upregulating vitamin K epoxide reductase and inhibiting thrombomodulin.
    Ge B, Zhang Z, Lam TT, Zuo Z.
    Biopharm Drug Dispos; 2017 Jan 22; 38(1):33-49. PubMed ID: 27925234
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Warfarin pharmacogenetics.
    Limdi NA, Veenstra DL.
    Pharmacotherapy; 2008 Sep 22; 28(9):1084-97. PubMed ID: 18752379
    [Abstract] [Full Text] [Related]

  • 15. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.
    J Thromb Thrombolysis; 2006 Dec 22; 22(3):191-7. PubMed ID: 17111199
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M, Brouwers JR, Schalekamp T, Wilffert B.
    Thromb Haemost; 2008 Dec 22; 100(6):1052-7. PubMed ID: 19132230
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events.
    Santos PC, Soares RA, Strunz CM, Grinberg M, Ferreira JF, Cesar LA, Scanavacca M, Krieger JE, Pereira AC.
    J Manag Care Spec Pharm; 2014 Apr 22; 20(4):376-81. PubMed ID: 24684642
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.